Research graph
References from Oxaliplatin-Based Platinum(IV) Prodrug Bearing Toll-like Receptor 7 Agonist for Enhanced Immunochemotherapy. Local targets link to admitted publications; unresolved targets remain external evidence.
Cellular processing of platinum anticancer drugs
10.1038/nrd1691 · 2005 · External reference
Targeted delivery of platinum-based anticancer complexes
10.1016/j.cbpa.2013.01.004 · 2013 · External reference
The resurgence of platinum-based cancer chemotherapy
10.1038/nrc2167 · 2007 · External reference
Toward Multi-Targeted Platinum and Ruthenium Drugs─A New Paradigm in Cancer Drug Treatment Regimens?
10.1021/acs.chemrev.8b00271 · 2019 · External reference
Platinum(iv) anticancer prodrugs - hypotheses and facts
10.1039/c6dt01414c · 2016 · External reference
Cisplatin in cancer therapy: Molecular mechanisms of action
10.1016/j.ejphar.2014.07.025 · 2014 · External reference
Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics
10.1158/1078-0432.ccr-13-3141 · 2014 · External reference
Metal Drugs and the Anticancer Immune Response
10.1021/acs.chemrev.8b00396 · 2019 · External reference
A Cisplatin-Loaded Immunochemotherapeutic Nanohybrid Bearing Immune Checkpoint Inhibitors for Enhanced Cervical Cancer Therapy
10.1002/anie.201800422 · 2018 · External reference
Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression
10.1038/s41467-017-01651-9 · 2017 · External reference
An Iron Oxide Nanocarrier Loaded with a Pt(IV) Prodrug and Immunostimulatory dsRNA for Combining Complementary Cancer Killing Effects
10.1002/adhm.201500080 · 2015 · External reference
A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy
10.1021/jacs.5b10182 · 2015 · External reference
Immuno-Chemotherapeutic Platinum(IV) Prodrugs of Cisplatin as Multimodal Anticancer Agents
10.1002/anie.201402879 · 2014 · External reference
A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress
10.1038/nm.4291 · 2017 · External reference
Nucleolar Stress Induction by Oxaliplatin and Derivatives
10.1021/jacs.9b10319 · 2019 · External reference
Immunogenic death of colon cancer cells treated with oxaliplatin
10.1038/onc.2009.356 · 2010 · External reference
Oxaliplatin: a review in the era of molecularly targeted therapy
10.3747/co.v18i1.708 · 2011 · External reference
Dendritic Cells: Immune Regulators in Health and Disease
10.1152/physrev.00023.2001 · 2002 · External reference
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
10.1038/nm1589 · 2007 · External reference
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
10.1038/ni.1863 · 2010 · External reference
TLR signalling and the function of dendritic cells
10.1159/000086657 · 2005 · External reference
The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice
10.1038/cmi.2010.30 · 2010 · External reference
Recognition of single-stranded RNA viruses by Toll-like receptor 7
10.1073/pnas.0400937101 · 2004 · External reference
Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma
10.1186/s13045-015-0121-9 · 2015 · External reference
Synergy of purine-scaffold TLR7 agonist with doxorubicin on systemic inhibition of lymphoma in mouse model
10.7150/jca.20015 · 2017 · External reference
Basis for design and development of platinum(IV) anticancer complexes
10.1021/jm070280u · 2007 · External reference
The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs
10.1021/acs.chemrev.5b00597 · 2016 · External reference
Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator
10.1002/anie.201604236 · 2016 · External reference
An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo
10.1039/c6sc03862j · 2017 · External reference
Mouse 4T1 breast tumor model
10.1002/0471142735.im2002s39 · 2000 · External reference
Light-driven transformable optical agent with adaptive functions for boosting cancer surgery outcomes
10.1038/s41467-018-04222-8 · 2018 · External reference
A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors
10.1038/s41467-018-03915-4 · 2018 · External reference
Immunological therapy: A novel thriving area for triple-negative breast cancer treatment
10.1016/j.canlet.2018.10.042 · 2019 · External reference
Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands
10.1016/j.jinorgbio.2014.07.004 · 2014 · External reference
Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action
10.1039/c5sc04205d · 2016 · External reference
Calreticulin exposure dictates the immunogenicity of cancer cell death
10.1038/nm1523 · 2007 · External reference
Immunogenic death of colon cancer cells treated with oxaliplatin
10.1038/onc.2009.356 · 2010 · External reference
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
10.1038/emboj.2011.497 · 2012 · External reference
Targeting cell surface TLR7 for therapeutic intervention in autoimmune diseases
10.1038/ncomms7119 · 2015 · External reference
Facile preparation of mono-, di- and mixed-carboxylato platinum(IV) complexes for versatile anticancer prodrug design
10.1002/chem.201203159 · 2013 · External reference
